11-0546_finalR.pdfVIP

Multidrug-Resistant Tuberculosis, People’s Republic of China, 2007–2009 1 1 Guang Xue He, Hai Ying Wang, Martien W. Borgdorff, Dick van Soolingen, Marieke J. van der Werf, Zhi Min Liu, Xue Zheng Li, Hui Guo, Yan Lin Zhao, Jay K. Varma, Christopher P. Tostado, and Susan van den Hof We conducted a case–control study to investigate risk Republic of China has the second greatest number of MDR factors for multidrug-resistant tuberculosis (MDR TB) in the TB cases in the world (2). According to the National People’s Republic of China. Genotyping analysis was used Anti-Tuberculosis Drug Resistance Survey in 2007, an to estimate the percentage of cases from recent transmission estimated 120,000 new MDR TB cases emerge annually among 100 MDR TB case-patients hospitalized during April in China, accounting for ≈24% of MDR TB worldwide 2007–July 2009. Molecular subtyping of isolates showed (3). Although MDR TB represents only 8% of incident that 41% of MDR TB strains clustered. Beijing genotype was found in 94% of the MDR TB isolates and 79% of the TB cases in China, controlling MDR TB is challenging pan-susceptible isolates. In multivariate analysis, MDR because it is diffi cult to diagnose and treat (4). Thus, MDR TB was independently associated with Beijing genotype, TB is increasingly becoming a serious threat to TB control retreatment for TB, symptoms lasting 3 months before (3,5), and the recognition of